XML 23 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:        
Net loss $ (25,873,000) $ (9,485,000) $ (17,971,000) $ (14,704,000)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock option compensation expense 48,000 138,000 161,000 349,000
Restricted stock compensation expense 84,000 228,000 266,000 308,000
Depreciation expense 198,000 232,000 305,000 617,000
Loss on disposal of equipment 20,000 1,000 1,000 15,000
Warrant liability fair value adjustment (1,227,000) (9,171,000) (12,780,000) (564,000)
Gain on warrant extinguishment (9,613,000) 0    
Non-cash interest income 16,000 (1,000) (1,000) (1,000)
Deferred revenue (30,000) 31,000    
Debt discount and deferred finance costs amortization 20,315,000 6,567,000 14,268,000  
Loss on debt settlements 2,952,000 0    
Changes in assets and liabilities:        
Decrease in prepaid expenses and other assets 276,000 610,000 260,000 9,000
Increase in accounts receivable (94,000) (94,000) (138,000) (52,000)
Decrease (increase) in inventories (338,000) 190,000 95,000 (420,000)
Increase (decrease) in accounts payable and accrued expenses 1,767,000 312,000 1,507,000 (1,757,000)
Increase in deferred revenue     30,000  
Decrease in other non-current liabilities (160,000) (155,000) (216,000) (220,000)
Net cash used in operating activities (11,659,000) (10,597,000) (14,213,000) (16,420,000)
Cash flows from investing activities:        
Purchase of property, plant and equipment (372,000) (245,000) (258,000) (170,000)
Increase in restricted cash 0 (1,087,000) (1,087,000)  
Proceeds from sales of property, plant and equipment       180,000
Net cash provided by (used in) investing activities (372,000) (1,332,000) (1,345,000) 10,000
Cash flows from financing activities:        
Increase in restricted cash 0 (29,200,000) (26,200,000)  
Net proceeds from the release of restricted cash 7,901,000 0    
Net proceeds from sale of Series B and Series C preferred shares 2,278,000 0    
Net proceeds from convertible debt financing 0 31,436,000 31,226,000  
Net proceeds from sale of stock and exercise of warrants 15,000 704,000 2,383,000 8,655,000
Net cash provided by financing activities 10,194,000 2,940,000 7,409,000 8,655,000
Foreign currency effects on cash and cash equivalents (77,000) 71,000 (49,000) (107,000)
Net decrease in cash and cash equivalents (1,914,000) (8,918,000) (8,198,000) (7,862,000)
Cash and cash equivalents:        
Beginning of period 4,409,000 12,607,000 12,607,000 20,469,000
End of period 2,495,000 3,689,000 4,409,000 12,607,000
Supplemental non-cash activities:        
Conversion of convertible notes 26,199,000 0 649,000  
Fair value of warrants issued 0 28,133,000 28,472,000 4,247,000
Fair value of warrants exercised 19,000 245,000 $ 726,000 $ 123,000
Series A and Series B Preferred Shares [Member]        
Cash flows from financing activities:        
Release of restricted cash for redemption of Series A and Series B preferred shares 2,360,000 0    
Redemption of Series A and Series B preferred shares (2,360,000) 0    
Series C Warrants [Member]        
Cash flows from financing activities:        
Release of restricted cash for extinguishment of Series C Warrants 7,876,000 0    
Cash paid to extinguish of Series C Warrants $ (7,876,000) $ 0